Castrate-Resistant Prostate Cancer (CRPC) represents an advanced stage of prostate cancer that no longer responds to traditional hormonal therapy aimed at lowering testosterone. This condition is particularly challenging to treat, necessitating innovative approaches and therapies. Understanding the dynamics of the castrate-resistant prostate cancer market is crucial for stakeholders, including healthcare providers, researchers, and pharmaceutical companies. […]
